378800.KQ Shaperon Inc.
- Market cap
- KRW 15.2B
- P/E
- -
- P/B
- 0.80x
- ROE
- -76.1%
- Dividend yield
- -
- Fundamental score
- 0.7/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 378800.KQ undervalued?
Graham numberThe Graham number of Shaperon Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shaperon Inc. fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-76.1%), below 10%.
ROA 0/1
Return on assets (-49.6%) is below the industry median (-10.1%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (22.8%) is above the industry median (4.8%).
Revenue Growth 0/2
Revenue shrank 51.5% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.1 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (0.8x) is below the industry median (2.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Shaperon Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shaperon Inc.
Shaperon Inc. develops therapies based on GPCR19-inflammasome inhibitor platform and NanoMab antibody platform for immune diseases. It offers NuGel which blocks the root cause of atopic dermatitis that is in Phase 2 clinical trials; NuDifin that calms wound inflammation and accelerates the regeneration of tissue; NuRalin indicated for atopic dermatitis; NuAreatin for the treatment of alopecia areata. The company also provides NuCerin, a pill designed to reduce neuroinflammat…
Full company profileShaperon Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shaperon Inc. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 2.00B | 215M | 17.7M | 228M | 213M |
| Gross Profit | 2.00B | 215M | 17.7M | -93.3M | -57.1M |
| Operating Income | -11.0B | -13.2B | -15.1B | -15.8B | -13.6B |
| EBITDA | -10.1B | -11.6B | -13.7B | -14.3B | -13.0B |
| Net Income | -10.7B | -12.4B | -14.9B | -15.5B | -14.5B |
| EPS | -418 | -473 | -435 | -336 | -313 |
| Balance Sheet | |||||
| Total Assets | 35.2B | 25.0B | 19.3B | 27.9B | 29.2B |
| Total Liabilities | 5.87B | 6.01B | 3.28B | 3.13B | 10.2B |
| Shareholders' Equity | 29.3B | 19.0B | 16.0B | 24.7B | 19.0B |
| Cash & Short-term Investments | 4.33B | 6.47B | 15.4B | 865M | 991M |
| Cash Flow | |||||
| Operating Cash Flow | -7.95B | -13.0B | -16.7B | -14.5B | -14.0B |
| Capital Expenditure | 187M | 1.93B | 564M | 405M | 208M |
| Free Cash Flow | -8.14B | -14.9B | -17.3B | -14.9B | -14.2B |
| Ratios | |||||
| ROE | -36.5% | -65.3% | -93.1% | -62.8% | -76.1% |
| ROA | -30.4% | -49.6% | -77.3% | -55.7% | -49.6% |
| Net Profit Margin | -533.6% | -5,762.3% | -84,176.3% | -6,816.3% | -6,793.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Shaperon Inc. dividends
Shaperon Inc. has not paid dividends in the last 4 fiscal years.
Last stock split: 1:5 on Sep 29, 2026.
Who owns Shaperon Inc.
- Insiders 16.54%
- Institutions 0.00%
- Public & others 83.46%
- Shares outstanding 6.86M
- Free float 8.18M
Shaperon Inc. company profile
- Company name
- Shaperon Inc.
- Ticker
- 378800.KQ
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 43
- Fiscal year end
- December
- Address
- 174-10 Jagok-ro, Seoul, South Korea
- Phone
- 82 2 6083 8315
- Website
- shaperon.com
About Shaperon Inc.
Shaperon Inc. develops therapies based on GPCR19-inflammasome inhibitor platform and NanoMab antibody platform for immune diseases. It offers NuGel which blocks the root cause of atopic dermatitis that is in Phase 2 clinical trials; NuDifin that calms wound inflammation and accelerates the regeneration of tissue; NuRalin indicated for atopic dermatitis; NuAreatin for the treatment of alopecia areata. The company also provides NuCerin, a pill designed to reduce neuroinflammation; NuSepin, which alleviates excessive systemic inflammation; and NuPulin for the treatment of inflammation-driven pulmonary fibrosis. In addition, it offers Papiliximab, a NanoMab-based bispecific antibody that blocks PD-L1 and CD47 for leukemia treatment; Ovizumab, a tumor-specific immunotherapy; Regtizumab, an anti-tumor immunity; and Rbody, a NanoMabs' small size which enables the creation of LNP-mRNA therapeutics. Further, the company provides RumiLua, a cosmeceutical ingredient to help prevent excessive skin responses while supporting the skin's natural balance and overall condition. The company was founded in 2008 and is headquartered in Seoul, South Korea.
Shaperon Inc. management
6- Seung-Yong Seong M.D., Ph.D.Founder & CEO
- Gene Yune B.S.Chief Financial Officer
- Seon-Ae Han Ph.D.Chief Clinical Development Officer
- Justin Oh J.D., M.S.Chief Business Officer
- Hyoung-Tae Kim Ph.D.Head of Innovation Center
- Ji-Hye Lee M.D.Chief Medical Officer